Search 

The Addario Lung Cancer Medical Institute (ALCMI), founded in 2008 as a 501c(3) non-profit organization, is a patient-centric, international research consortium driving research otherwise not possible, evidenced by ALCMI's current clinical studies CASTLE, INHERIT EGFR T790M, Genomics of Young Lung Cancer and others. ALCMI overcomes barriers to collaboration via a world-class team of investigators from 21+ institutions in the U.S., France, Italy, Spain and U.K., supported by dedicated research infrastructures such as centralized project management, tissue banks and data systems. ALCMI directly facilitates research by combining scientific expertise found at leading academic institutions with patient access through our network of community cancer centers – accelerating novel research advancements to lung cancer patients. 

“AdeTherapeutics’ approach has potential to become standard of care,” says Dr. Greenberg, Vice Chair Obs & Gyn at Brigham and Women’s Hospital and Associate Professor at Harvard Medical School.

Our platform technology which KOL’s have pointed out as a game changer in the area of preventing post operative fibrosis, is poised to create significant value.  The pipeline contains a phase II drug for prevention of post operative fibrosis following pelvic and abdominal surgeries, med devices (collaboration with DSM Biomedical) for spinal surgery and additional opportunities in orthopedics.  

The Company has built a world class team, utilized a capital efficient, highly targeted and focused approach and brought on the necessary strategic partners to bring first-in-class products to the market and establish standard of care for millions of surgeries worldwide.Key value propositions:

•             useful in more procedures than current medical devices

•             significant higher efficacy vs market comparators

•             attractive safety profile & accelerated regulatory pathway

Key Milestones achieved:

• Phase II trial started
• Key markets patents issued: USA, EU, Japan
• Efficacy shown in different tissues areas
• Two peer reviewed publications in 2014

Advent Life Sciences

We invest predominantly in early and mid-stage life sciences companies.  We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.

Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.

Real people. Real insight. Real value.

Innovation. Clarity. Execution.

Antibody Solutions is a premier developer of therapeutic, diagnostic and critical reagent antibodies. Our platforms include human antibodies from transgenic OmniRats™, Hybridoma Libraries™, and high-throughput flow-cytometry screening of cell-associated targets. We provide full technical support and project management with all services performed in the USA. 

Apple Tree Partners is a private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spinouts to $150 million dollar in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.